{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '150', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'IUD', 'intrauterine device', 'iUPD', 'unconfirmed PD', 'IUS', 'intrauterine hormone-releasing system', 'IV', 'intravenous', 'KL-6', 'Krebs von den Lungen-6', 'LEAP', 'lenvatinib and pembrolizumab', 'LVEF', 'left ventricular ejection fraction', 'mAb', 'monoclonal antibody', 'MRI', 'magnetic resonance imaging', 'MTD', 'maximum tolerated dose', 'MUGA', 'multigated acquisition scan', 'NCI', 'National Cancer Institute', 'NSCLC', 'non-small cell lung cancer', 'OR', 'objective response', 'ORR', 'objective response rate', 'os', 'overall survival', 'PD', 'progressive disease', 'PD-1', 'programmed cell death protein', 'PDGFR', 'platelet-derived growth factor receptor', 'PD-L1', 'programmed cell death ligand 1', 'PD-L2', 'programmed cell death ligand 2', 'PFS', 'progression-free survival', 'Pgp', 'P-glycoprotein', 'PK', 'pharmacokinetic', 'PopPK', 'population pharmacokinetics', 'PR', 'partial response', 'PRES', 'posterior reversible encephalopathy syndrome', 'PRO', 'patient-reported outcomes', 'Q3W', 'every 3 weeks', 'QD', 'once daily', 'QLQ-LC13', 'Quality of Life Questionnaire and Lung Cancer Module 13', 'QoL', 'quality of life', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '151', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'RCC', 'renal cell carcinoma', 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors 1.1', 'RNA', 'ribonucleic acid', 'RP2D', 'recommended Phase 2 dose', 'RPLS', 'reversible posterior leukoencephalopathy syndrome', 'RTKi', 'receptor tyrosine kinase inhibitor', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SD', 'stable disease', 'SoA', 'schedule of activities', 'SOC', 'standard of care', 'SP-D', 'surfactant protein-D', 'SpO2', 'peripheral capillary oxygen saturation', 'sSAP', 'supplemental statistical analysis plan', 'TAM', 'tumor-associated macrophage', 'TB', 'tuberculosis', 'TPS', 'tumor proportion score', 'TTD', 'time to true deterioration', 'UPCR', 'urine protein-to-creatinine ratio', 'V', 'volume of distribution', 'VEGF', 'vascular endothelial growth factor', 'VEGFR', 'vascular endothelial growth factor receptor', 'WOCBP', 'woman/women of childbearing potential', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '152', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '11 REFERENCES', '[Aaronson, N. K., et al 1993]', 'Aaronson NK, Ahmedzai S, Bergman', '[03Q3QL]', 'B, Bullinger M, Cull A, Duez NJ, et', 'al. The European Organization for', 'Research and Treatment of Cancer', 'QLQ-C30: a quality-of-life instrument', 'for use in international clinical trials in', 'oncology. J Natl Cancer Inst', '1993;85(5):365-76.', '[Bergman, B., et al 1994]', 'Bergman B, Aaronson NK, Ahmedzai', '[00VTZB]', 'S, Kaasa S, Sullivan M. The EORTC', 'QLQ-LC13: a modular supplement to', 'the EORTC core quality of life', 'questionnaire (QLQ-C30) for use in', 'lung cancer clinical trials. Eur J', 'Cancer 1994;30A(5):635-42.', '[Cross, M. J. 2001]', 'Cross MJ, Claesson-Welsh L. FGF', '[04XKP6]', 'and VEGF function in angiogenesis:', 'signalling pathways, biological', 'responses and therapeutic inhibition.', 'Trends Pharmacol Sci. 2001', 'Apr;22(4):201-7.', '[Disis, M. L. 2010]', 'Disis ML. Immune regulation of', '[058SQL]', 'cancer. J Clin Oncol', '2010;28(29):4531-8.', '[Dudley, M. E., et al 2005]', 'Dudley ME, Wunderlich JR, Yang JC, [00VMPR]', 'Sherry RM, Topalian SL, Restifo NP,', 'et al. Adoptive cell transfer therapy', 'following non-myeloablative but', 'lymphodepleting chemotherapy for the', 'treatment of patients with refractory', 'metastatic melanoma. J Clin Oncol', '2005;23(10):2346-57.', '[Ellis, L. M. 2008]', 'Ellis LM, Hicklin DJ. VEGF-targeted', '[04XKPD]', 'therapy: mechanisms of anti-tumour', 'activity. Nat Rev Cancer. 2008', 'Aug;8:579-91.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}